
## Dhananjay Arun Chitale

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4512471/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20932-20937.	3.3	1,557
2	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology, 2013, 8, 823-859.	0.5	792
3	Frequency and Distinctive Spectrum of <i>KRAS</i> Mutations in Never Smokers with Lung Adenocarcinoma. Clinical Cancer Research, 2008, 14, 5731-5734.	3.2	505
4	Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for <i>BRAF, PIK3CA</i> , and <i>AKT1</i> . Cancer Research, 2009, 69, 4885-4893.	0.4	488
5	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Archives of Pathology and Laboratory Medicine. 2013. 137. 828-860.	1.2	415
6	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. Journal of Molecular Diagnostics, 2013, 15, 415-453.	1.2	397
7	Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma. Journal of Thoracic Oncology, 2008, 3, 111-116.	0.5	248
8	Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer. Cancer Research, 2010, 70, 5901-5911.	0.4	245
9	Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer. Cancer Research, 2008, 68, 9375-9383.	0.4	235
10	Novel <i>MEK1</i> Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma. Cancer Research, 2008, 68, 5524-5528.	0.4	206
11	An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene, 2009, 28, 2773-2783.	2.6	205
12	Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases. Clinical Cancer Research, 2008, 14, 1938-1946.	3.2	193
13	Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM. PLoS ONE, 2012, 7, e33729.	1.1	189
14	EGFR Mutations in Lung Adenocarcinomas. Journal of Molecular Diagnostics, 2008, 10, 242-248.	1.2	180
15	Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans. Journal of Thoracic Oncology, 2011, 6, 28-31.	0.5	126
16	Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells. Scientific Reports, 2017, 7, 8760.	1.6	119
17	False-negative core needle biopsies of the breast. Cancer, 2003, 97, 1824-1831.	2.0	109
18	Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. American Journal of Translational Research (discontinued), 2012, 4, 14-23.	0.0	70

#	Article	IF	CITATIONS
19	Comparative Analysis of Breast Cancer Phenotypes in African American, White American, and West Versus East African patients: Correlation Between African Ancestry and Triple-Negative Breast Cancer. Annals of Surgical Oncology, 2016, 23, 3843-3849.	0.7	63
20	Mutational Landscape of Aggressive Prostate Tumors in African American Men. Cancer Research, 2016, 76, 1860-1868.	0.4	61
21	Renal Cell Carcinoma With Chromosome 6p Amplification Including the TFEB Gene. American Journal of Surgical Pathology, 2017, 41, 287-298.	2.1	60
22	Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. Modern Pathology, 2012, 25, 1023-1032.	2.9	57
23	Hereditary Susceptibility for Triple Negative Breast Cancer Associated With Western Sub-Saharan African Ancestry. Annals of Surgery, 2019, 270, 484-492.	2.1	56
24	A serum-based DNA methylation assay provides accurate detection of glioma. Neuro-Oncology, 2021, 23, 1494-1508.	0.6	53
25	Adenomyoepithelioma of the Breast: A Brief Diagnostic Review. Archives of Pathology and Laboratory Medicine, 2013, 137, 725-729.	1.2	51
26	Inhibition of 5-Lipoxygenase Selectively Triggers Disruption of c-Myc Signaling in Prostate Cancer Cells. Journal of Biological Chemistry, 2015, 290, 4994-5006.	1.6	50
27	Benign metastasizing chondroblastoma. Cancer, 1998, 82, 675-678.	2.0	47
28	The Role of Lymph Node Metastasis in the Systemic Dissemination of Breast Cancer. Annals of Surgical Oncology, 2009, 16, 3396-3405.	0.7	44
29	Clinical Performance of <i>JAK2</i> V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory. American Journal of Clinical Pathology, 2009, 132, 713-721.	0.4	41
30	Atypical Chemokine Receptor 1 ( <i>DARC/ACKR1</i> ) in Breast Tumors Is Associated with Survival, Circulating Chemokines, Tumor-Infiltrating Immune Cells, and African Ancestry. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 690-700.	1.1	41
31	Methylation of the RARB Gene Increases Prostate Cancer Risk in Black Americans. Journal of Urology, 2013, 190, 317-324.	0.2	36
32	DNA Methylation in Thyroid Tumorigenesis. Cancers, 2011, 3, 1732-1743.	1.7	34
33	Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis. BMC Cancer, 2015, 15, 407.	1.1	34
34	Triple-Negative Breast Cancer, Stem Cells, and African Ancestry. American Journal of Pathology, 2018, 188, 271-279.	1.9	33
35	Admixture Fine-Mapping in African Americans Implicates XAF1 as a Possible Sarcoidosis Risk Gene. PLoS ONE, 2014, 9, e92646.	1.1	31
36	Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database. Modern Pathology, 2017, 30, 1603-1612.	2.9	30

#	Article	IF	CITATIONS
37	Expression of cancer–testis antigens in endometrial carcinomas using a tissue microarray. Modern Pathology, 2005, 18, 119-126.	2.9	28
38	Angiolipoma of the Female Breast: Clinicomorphological Correlation of 52 Cases. International Journal of Surgical Pathology, 2011, 19, 35-43.	0.4	27
39	Differential expression of aurora-A kinase in T-cell lymphomas. Modern Pathology, 2013, 26, 640-647.	2.9	25
40	Prevalence of Terminal Duct Lobular Units and Frequency of Neoplastic Involvement of the Nipple in Mastectomy. Archives of Pathology and Laboratory Medicine, 2013, 137, 955-960.	1.2	25
41	The Henry Ford Production System: LEAN Process Redesign Improves Service in the Molecular Diagnostic Laboratory. Journal of Molecular Diagnostics, 2009, 11, 390-399.	1.2	22
42	Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. Modern Pathology, 2013, 26, 1197-1203.	2.9	22
43	Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer. Genes Chromosomes and Cancer, 2018, 57, 19-27.	1.5	22
44	Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women. Breast Cancer Research and Treatment, 2012, 131, 561-570.	1.1	19
45	Biological significance of genomeâ€wide DNA methylation profiles in keloids. Laryngoscope, 2017, 127, 70-78.	1.1	19
46	Methylation Markers for Early Detection and Differentiation of Follicular Thyroid Cancer Subtypes. Cancer and Clinical Oncology, 2015, 4, 1-12.	0.2	17
47	Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival. BMC Medical Genomics, 2020, 13, 116.	0.7	17
48	Intraoperative Clinical Assessment and Pressure Measurements of Sentinel Lymph Nodes in Breast Cancer. Annals of Surgical Oncology, 2014, 21, 81-85.	0.7	15
49	Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens. International Journal of Molecular Sciences, 2017, 18, 627.	1.8	15
50	Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer. Neoplasia, 2019, 21, 989-1002.	2.3	15
51	Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, <i>ETV1</i> , and <i>ETV4</i> on wholeâ€mount radical prostatectomy tissue. Prostate, 2020, 80, 38-50.	1.2	15
52	Gene fusion characterisation of rare aggressive prostate cancer variants—adenosquamous carcinoma, pleomorphic giantâ€cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. Histopathology, 2020, 77, 890-899.	1.6	15
53	Precursor Lesions of Mucinous Carcinoma of the Breast. American Journal of Surgical Pathology, 2013, 37, 1076-1084.	2.1	14
54	Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack <i>USP6</i> , <i> ROS1</i> and <i>ETV6</i> gene rearrangements. Histopathology, 2018, 73, 321-326.	1.6	14

#	Article	IF	CITATIONS
55	Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. Journal of Trace Elements in Medicine and Biology, 2018, 48, 233-238.	1.5	13
56	Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer. International Journal of Cancer, 2016, 138, 2884-2893.	2.3	12
57	Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk. Prostate, 2017, 77, 949-954.	1.2	12
58	Investigation of triple-negative breast cancer risk alleles in an International African-enriched cohort. Scientific Reports, 2021, 11, 9247.	1.6	12
59	Anti-centrosome antibodies in breast cancer are the expression of autoimmunity. Immunologic Research, 2014, 60, 339-347.	1.3	11
60	The interplay of growth differentiation factor 15 (GDF15) expression and M2 macrophages during prostate carcinogenesis. Carcinogenesis, 2020, 41, 1074-1082.	1.3	11
61	Growth and differentiation factor 15 and NFâ€ÎºB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection. Cancer Medicine, 2021, 10, 3013-3025.	1.3	10
62	A pediatric case of pigmented epithelioid melanocytoma with chromosomal copy number alterations in 15q and 17q and a novel <i>NTRK3â€SCAPER</i> gene fusion. Journal of Cutaneous Pathology, 2020, 47, 70-75.	0.7	9
63	The biological significance of methylome differences in human papilloma virus associated head and neck cancer. Oncology Letters, 2016, 12, 4949-4956.	0.8	8
64	Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2018, 25, 1921-1927.	0.7	8
65	Pleomorphic fibroma of the skin with MDM2 immunoreactivity: A potential diagnostic pitfall. Journal of Cutaneous Pathology, 2018, 45, 59-62.	0.7	8
66	Race Differences in Telomere Length in Benign Prostate Biopsies and Subsequent Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 991-998.	1.1	8
67	Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry. Breast Cancer Research and Treatment, 2021, 186, 391-401.	1.1	7
68	Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization. Modern Pathology, 2020, 33, 1791-1801.	2.9	6
69	Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients. American Journal of Translational Research (discontinued), 2016, 8, 166-76.	0.0	6
70	Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories. BMC Research Notes, 2012, 5, 196.	0.6	4
71	Germline and Somatic <i>NF1</i> Alterations Are Linked to Increased HER2 Expression in Breast Cancer. Cancer Prevention Research, 2018, 11, 655-664.	0.7	4
72	Distribution and Shortâ€ŧerm Prognostic Value of the 21â€gene recurrence score in African American compared to White American breast cancer patients. Breast Journal, 2019, 25, 667-671.	0.4	4

#	Article	IF	CITATIONS
73	Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents. Modern Pathology, 2021, 34, 720-734.	2.9	4
74	Racial differences in the systemic inflammatory response to prostate cancer. PLoS ONE, 2021, 16, e0252951.	1.1	4
75	Customizable Natural Language Processing Biomarker Extraction Tool. JCO Clinical Cancer Informatics, 2021, 5, 833-841.	1.0	4
76	Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. Journal of Biological Chemistry, 2022, 298, 101556.	1.6	4
77	Investigation into the presence of human papillomavirus in patients with obstructive sleep apnea. Laryngoscope, 2017, 127, 1231-1234.	1.1	3
78	A Novel <i>COL1A1-CAMTA1</i> Rearrangement in Cranial Fasciitis. International Journal of Surgical Pathology, 2020, 28, 678-682.	0.4	3
79	Array-CGH Shows Amplification of 8q Including <b><i>MYC</i></b> as the Sole Aberration in a Leiomyosarcoma of the Female Lower Genital Tract. Cytogenetic and Genome Research, 2014, 142, 245-248.	0.6	2
80	Potential effect of antiâ€inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy. Prostate, 2019, 79, 1090-1098.	1.2	2
81	Intraspinal Endodermal Cyst: Ultrastructural Study of Abnormal Cilia. Microscopy and Microanalysis, 2003, 9, 183-189.	0.2	1
82	The Potential and Limitations of Precision Oncology: Lessons Learned from Whole-Exome Sequencing in an Exceptional Response to Everolimus in Advanced Renal Cell Carcinoma. Case Reports in Oncology, 2021, 14, 1194-1200.	0.3	1
83	The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors Journal of Clinical Oncology, 2013, 31, 11085-11085.	0.8	1
84	Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study. BMJ Open, 2021, 11, e053397.	0.8	1
85	Lung and Mediastinal Tumors. , 2015, , 221-268.		Ο
86	Assessment of the Immune Microenvironment in Estrogen Receptor Positive Invasive Breast Cancers and Its Correlation to Clinicopathologic Parameters. American Journal of Clinical Pathology, 2016, 146, .	0.4	0
87	HER2 Expression in NF1 Breast Cancer—Response. Cancer Prevention Research, 2019, 12, 197-198.	0.7	0
88	Ecchymotic Nodule on the Scalp: Answer. American Journal of Dermatopathology, 2019, 41, 612-613.	0.3	0
89	Ecchymotic Nodule on the Scalp: Challenge. American Journal of Dermatopathology, 2019, 41, e78-e79.	0.3	0
90	The effects of BR-DIM (BioResponse 3, 3'-Diindolylmethane) administered pre-prostatectomyÂon the androgen receptor (AR) Journal of Clinical Oncology, 2012, 30, 1560-1560.	0.8	0

#	Article	IF	CITATIONS
91	Implementation of precision medicine clinical care pathways and a systemwide molecular tumor board at Henry Ford Health System (HFHS) Journal of Clinical Oncology, 2018, 36, e18541-e18541.	0.8	Ο

Ancillary Studies: Contribution to Error and Error Prevention. , 2019, , 77-106.

0